Sangamo Sinks Most in a Decade as Gene-Editing Study Fizzles

Sangamo Therapeutics Inc. tumbled 48 percent, the most in a decade, after a pair of early-stage studies failed to demonstrate the benefit of two gene-editing medicines. Peers that employ CRISPR gene-editing technology also sank to session lows.